败血症中的血小板相关免疫球蛋白 - Suppr | 超能文献

Platelet-associated IgG in septicemia.

作者信息

Duedari N, George C, Cacitti A M, Sabatier C, Mannoni P, Rapin M

出版信息

N Engl J Med. 1979 Aug 2;301(5):271-2.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Platelet-associated IgG in septicemia.败血症中的血小板相关免疫球蛋白

N Engl J Med. 1979 Aug 2;301(5):271-2.

2

Platelet-associated IgG in septicemia.败血症中的血小板相关免疫球蛋白

N Engl J Med. 1979 Aug 2;301(5):272.

3

Elevated platelet-associated IgG in the thrombocytopenia of septicemia.败血症血小板减少症中血小板相关IgG升高。

N Engl J Med. 1979 Apr 5;300(14):760-4. doi: 10.1056/NEJM197904053001404.

4

Platelet-associated IgG in septicemia.败血症中的血小板相关免疫球蛋白

N Engl J Med. 1979 Aug 2;301(5):271.

5

[Fluorescent patterns of platelet associated IgG as a autoantibody and IgG bound Fc receptor on platelet by fluorescent antibody technique and immune complex in serum of patients with various thrombocytopenia (author's transl)].用荧光抗体技术检测各种血小板减少症患者血清中作为自身抗体的血小板相关IgG、血小板上IgG结合的Fc受体的荧光模式及免疫复合物（作者译）

Rinsho Byori. 1981 May;29(5):517-24.

6

Circulating immune complexes and platelet IgG in various diseases.多种疾病中的循环免疫复合物和血小板IgG

Clin Exp Immunol. 1984 Dec;58(3):672-6.

7

[Platelet-associated immunoglobulin G (PAIgG) and circulating immune complexes in asymptomatic and symptomatic HIV-seropositive patients].无症状和有症状的HIV血清阳性患者的血小板相关免疫球蛋白G（PAIgG）和循环免疫复合物

Schweiz Med Wochenschr. 1988 Dec 10;118(49):1847-50.

8

Association of increased immune complexes, platelet IgG and serum IgG in chronic active hepatitis.慢性活动性肝炎中免疫复合物、血小板IgG及血清IgG升高的相关性

Clin Exp Immunol. 1983 Dec;54(3):655-60.

9

Thrombocytopenia of sepsis. The role of circulating IgG-containing immune complexes.脓毒症血小板减少症。循环中含IgG免疫复合物的作用。

Arch Intern Med. 1985 May;145(5):891-4. doi: 10.1001/archinte.145.5.891.

10

Detection and quantitation of platelet-associated IgG in thrombocytopenia: a comparison of immunofluorescence and immunoenzyme techniques.血小板减少症中血小板相关IgG的检测与定量：免疫荧光法与免疫酶法的比较

Med Lab Sci. 1989 Jan;46(1):45-9.